Nuevocor Welcomes Dr. Thierry Abribat to its Board of Directors

Nuevocor Strengthens Its Leadership with New Appointment



Nuevocor, a biotechnology company headquartered in Singapore, has recently announced the significant appointment of Dr. Thierry Abribat to its Board of Directors. This move is seen as a strategic enhancement of their leadership team as the company progresses towards clinical trials of its pioneering gene therapy designed to treat specific types of genetic cardiomyopathies.

Dr. Thierry Abribat joins Nuevocor with an impressive background in the biotech industry. He is recognized for his entrepreneurial spirit and has founded, led, and successfully exited numerous biotech firms, focusing on therapies that address critical medical needs. His most recent achievement was orchestrating a landmark acquisition of Amolyt Pharma for $1 billion by AstraZeneca, which reflects his expertise in steering companies towards impactful market positions.

Beyond Amolyt Pharma, Dr. Abribat has also been involved with companies such as Alizé Pharma, acquired by Millendo Therapeutics, and Alizé Pharma 2, which was taken over by Jazz Pharmaceuticals. He has held several leadership roles in drug development, business development, and general management, showcasing his multifaceted experience within the sector. His academic background includes a Doctor of Veterinary Medicine and a PhD in neuroendocrinology from the National Polytechnic Institute of Toulouse.

Upon joining Nuevocor, Dr. Abribat expressed his enthusiasm for the company’s mission. "I am excited to join Nuevocor at such a pivotal time in its journey toward becoming a clinical-stage company. Nuevocor's innovative mechanobiology-based approach has the potential to transform treatment for patients suffering from devastating genetic cardiomyopathies," he stated. This sentiment underscores the urgency and importance of advancing therapies that could make a real difference in patient lives.

Dr. Andreas Wallnöfer, the Chairman of the Board, welcomed Dr. Abribat's addition, stating, "We are honored to welcome Dr. Thierry Abribat to Nuevocor's Board of Directors. His extensive background and formidable achievements in biotech entrepreneurship will be crucial as we transition to a clinical-stage company and expand our presence in Europe."

Nuevocor focuses on developing novel therapies to treat genetic cardiomyopathies caused by disruptions in mechanobiology. Their groundbreaking therapy, NVC-001, represents a first-in-class AAV-based gene therapy aimed specifically at LMNA-related dilated cardiomyopathy (LMNA DCM). This condition is known for its aggressive progression towards severe heart failure and sudden cardiac death. NVC-001 is designed to improve the structural integrity of the nuclear envelope, a critical element in combatting this form of cardiomyopathy.

In preclinical studies, NVC-001 has demonstrated significant advantages regarding cardiac function and overall survival. The company aims to initiate Phase 1/2 clinical trials in early 2026 across various sites in both the U.S. and Europe, a development eagerly anticipated by the medical community.

At the core of Nuevocor’s innovative approach is its proprietary PrOSIA mechanobiology platform. This pioneering technology allows the company to address shared disease pathways across multiple types of cardiomyopathies—surpassing the traditional limitations of gene replacement therapies that typically target individual genetic mutations. By focusing on the underlying mechanisms driving these diseases, Nuevocor seeks to offer new hope to patients who currently have no effective treatment options.

In summary, the addition of Dr. Thierry Abribat to Nuevocor’s Board of Directors not only strengthens the existing leadership but also showcases the company's commitment to revolutionizing treatment for genetic cardiomyopathies. As they venture toward clinical trials, the anticipation builds around the potential impact of their innovative therapies on the lives of patients worldwide. The collaboration with experienced leaders like Dr. Abribat is poised to propel Nuevocor toward a promising future in biotechnology and healthcare.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.